Neutral sphingomyelinase 2 inhibitors based on the 4-(1H-imidazol-2-yl)-2,6-dialkoxyphenol scaffold
作者:Ondrej Stepanek、Niyada Hin、Ajit G. Thomas、Ranjeet P. Dash、Jesse Alt、Rana Rais、Camilo Rojas、Barbara S. Slusher、Takashi Tsukamoto
DOI:10.1016/j.ejmech.2019.03.015
日期:2019.5
Neutral sphingomyelinase 2 (nSMase2), a key enzyme in ceramide biosynthesis, is a new therapeutic target for the treatment of neurological disorders and cancer. Using 2,6-dimethoxy-4-[4-phenyl-5-(2-thienyl)-1H-imidazol-2-yl]phenol (DPTIP), our initial hit compound (IC50 = 30 nM) from nSMase2 screening efforts, as a molecular template, a series of 4-(1H-imidazol-2-yl)-2,6-dialkoxyphenol derivatives
中性鞘磷脂酶 2 (nSMase2) 是神经酰胺生物合成中的关键酶,是治疗神经系统疾病和癌症的新治疗靶点。使用 2,6-二甲氧基-4-[4-苯基-5-(2-噻吩基)-1 H-咪唑-2-基]苯酚 (DPTIP),我们 从 nSMase2 筛选得到的初始命中化合物 (IC 50 = 30 nM)努力,作为分子模板,设计、合成和评估了一系列 4-(1 H-咪唑-2-基)-2,6-二烷氧基苯酚衍生物。对 DPTIP 各个区域的系统检查确定了有效抑制 nSMase2 所需的关键药效团以及许多具有 4-(1 H-imidazol-2-yl)-2,6-dialkoxyphenol scaffold 与 DPTIP 相比,对 nSMase2 具有相似或更高的抑制效力。其中,4-(4,5-diisopropyl- 1H -imidazol-2-yl)-2,6-dimethoxyphenol ( 25b )